

CDRT4 (L-19): sc-246250

BACKGROUND

CDRT4 (CMT1A duplicated region transcript 4) is a 151 amino acid protein that is expressed in kidney and skeletal muscle, and is encoded by a gene located on human chromosome 17. Chromosome 17 comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

REFERENCES

- Hall, J.M., et al. 1992. Closing in on a breast cancer gene on chromosome 17q. *Am. J. Hum. Genet.* 50: 1235-1242.
- Evans, S.C. and Lozano, G. 1997. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. *Mol. Med. Today* 3: 390-395.
- Varley, J.M., et al. 1997. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. *Oncogene* 14: 865-871.
- Kersemaekers, A.M., et al. 1998. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. *Br. J. Cancer* 77: 192-200.
- Soussi, T., et al. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. *Hum. Mutat.* 15: 105-113.
- Piura, B., et al. 2001. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 97: 241-244.
- Inoue, K., et al. 2001. The 1.4-Mb CMT1A duplication/HNPP deletion genomic region reveals unique genome architectural features and provides insights into the recent evolution of new genes. *Genome Res.* 11: 1018-1033.

CHROMOSOMAL LOCATION

Genetic locus: *Cdrt4* (mouse) mapping to 11 B2.

SOURCE

CDRT4 (L-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of CDRT4 of mouse origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-246250 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

CDRT4 (L-19) is recommended for detection of CDRT4 of mouse origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with other CDRT family members.

Suitable for use as control antibody for CDRT4 siRNA (m): sc-142237, CDRT4 shRNA Plasmid (m): sc-142237-SH and CDRT4 shRNA (m) Lentiviral Particles: sc-142237-V.

Molecular Weight of CDRT4: 18 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.